Najat Khan files Rule 144 to sell RXRX shares

Najat Khan filed a Rule 144 notice to sell Common Stock of Recursion Pharmaceuticals.

Rhea-AI Filing Summary

Najat Khan filed a Rule 144 notice to sell Common Stock of Recursion Pharmaceuticals. The filing lists intended sales dated 05/15/2026 of 18,422 shares and 7,788 shares described as Equity Compensation. The excerpt also reports a prior sale of 28,298 shares on 03/09/2026 for $94,662.47.

Insights

Securities Compliance Analyst

Rule 144 notice documents planned resale of restricted or control stock.

The filing lists specific share amounts and sale dates: 18,422 and 7,788 shares dated 05/15/2026, labeled as Equity Compensation. These entries indicate scheduled dispositions under resale rules rather than new issuances.

Cash‑flow treatment is not stated beyond the prior sale showing $94,662.47 for 28,298 shares on 03/09/2026. Subsequent filings or broker confirmations will show whether these planned sales occurred.

Key Figures

Planned sale: 18,422 shares Planned sale: 7,788 shares Recent sale: 28,298 shares

3 metrics

Planned sale 18,422 shares dated 05/15/2026, Equity Compensation

Planned sale 7,788 shares dated 05/15/2026, Equity Compensation

Recent sale 28,298 shares sold on 03/09/2026 for $94,662.47

Key Terms

Rule 144, Equity Compensation, Common Stock

3 terms

Rule 144 regulatory

"144: Securities To Be Sold"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Equity Compensation financial

"Common | 05/15/2026 | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

Common Stock market

"Common | Merrill Lynch 301 Tresser Blvd."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Rule 144 filing for RXRX disclose?

It disclosed planned sales of Common Stock dated 05/15/2026, including 18,422 and 7,788 shares described as Equity Compensation, and a prior sale of 28,298 shares on 03/09/2026.

Who is the selling person named in the RXRX excerpt?

The excerpt names Najat Khan in the "Securities Sold During The Past 3 Months" section as having sold 28,298 shares on 03/09/2026, with proceeds shown as $94,662.47.

Are the 05/15/2026 sales in the filing primary issuances or resale notices?

They are presented as resale notices under Rule 144 and labeled Equity Compensation, indicating planned dispositions rather than primary company issuances or new offerings.

Does the filing state who will receive proceeds from the planned sales?

The provided excerpt does not specify the recipient of sale proceeds; it lists share counts and dates but does not state the cash‑flow treatment for the planned 05/15/2026 transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 01:29 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002020969
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Recursion Pharmaceuticals, Inc.
SEC File Number	001-40323
Address of Issuer	41 S Rio Grande Street Salt Lake City UTAH 84101
Phone	385-269-0203
Name of Person for Whose Account the Securities are To Be Sold	Najat Khan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 301 Tresser Blvd. Stamford CT 06901	23588	84459.2	524677865	06/05/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/15/2026	Equity Compensation	Recursion Pharmaceuticals			18422	05/15/2026	Equity Compensation
Common	05/15/2026	Equity Compensation	Recursion Pharmaceuticals			7788	05/15/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Najat Khan 41 S Rio Grande Street Salt Lake City UT 84101	Common	03/09/2026	28298	94662.47

144: Remarks and Signature

Remarks
Date of Notice	06/05/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/22/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Najat Khan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)